International Flavors & Fragrances Financial Model
Chemicals Company Financials Example (Free Excel Download)
International Flavors & Fragrances (IFF) is a global leader in the creation of value-added ingredients for the food, beverage, health, biosciences, and scent markets.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and credit analysis platform for International Flavors & Fragrances (IFF), enabling analysts to forecast the company's deleveraging trajectory and margin recovery following the transformational divestiture of its Pharma Solutions business and the 2025 restructuring of its Nourish segment.
International Flavors & Fragrances (IFF) is a global leader in the creation of value-added ingredients for the food, beverage, health, biosciences, and scent markets. The company leverages deep R&D capabilities to produce proprietary formulations that serve as critical, low-cost components in consumer packaged goods.
Business segments (based on 2024 reporting):
- Nourish (~51% of revenue): Provides flavour compounds and functional food ingredients.
- Scent (~21% of revenue): Creates fragrance compounds for fine perfumes and consumer products.
- Health & Biosciences (~19% of revenue): Develops enzymes, cultures, and probiotics for dietary supplements and industrial uses.
- Pharma Solutions (~9% of revenue): Produces pharmaceutical excipients (divested to Roquette in May 2025).
The United States accounts for approximately 28% of sales, with the remainder highly diversified globally. IFF operates a B2B, asset-moderate business model characterised by high R&D intensity, sticky customer relationships, and significant pricing power. The company competes in a consolidated oligopoly alongside Givaudan, Symrise, and dsm-firmenich. Recently, IFF has focused on aggressive deleveraging following its debt-heavy 2021 merger with DuPont's Nutrition & Biosciences division, culminating in the $2.85 billion sale of Pharma Solutions and the restructuring of the Nourish segment into "Taste" and "Food Ingredients" effective January 2025.
The downloadable International Flavors & Fragrances financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsInternational Flavors & Fragrances financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.66B | $12.44B | $11.48B | $11.48B | $10.89B |
| Gross profit | $3.73B | $4.15B | $3.68B | $4.12B | $3.94B |
| Operating income | $585.0M | -$1.33B | -$2.11B | $766.0M | -$382.0M |
| Net income | $279.0M | -$1.86B | -$2.59B | $267.0M | -$359.0M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for International Flavors & Fragrances
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Nourish
- Segment name: Nourish (Note: Restructured into Taste and Food Ingredients in 2025)
- Revenue driver formula: Prior Year Revenue x (1 + Volume Growth + Price/Mix Impact)
- Historical growth rate: Flat to 4% currency-neutral growth.
- Key growth levers and headwinds: Strong demand in core flavours offset by recent volume softness and pricing pressure in functional ingredients.
- Pricing dynamics: Value-based pricing with raw material cost pass-through mechanisms.
- Revenue recognition notes: Recognised at a point in time upon shipment or delivery.
- Seasonality: Mildly stronger in the first half of the year as consumer packaged goods customers build inventory for summer beverage and food consumption.
Scent
- Segment name: Scent
- Revenue driver formula: Prior Year Revenue x (1 + Fine Fragrance Growth + Consumer Fragrance Growth)
- Historical growth rate: 5% to 12% currency-neutral growth.
- Key growth levers and headwinds: Premiumisation in fine fragrances and strong volume recovery in consumer goods.
- Pricing dynamics: Highly contractual, with long-term briefs won from major consumer goods companies.
- Revenue recognition notes: Point in time upon transfer of control.
- Seasonality: Stronger in Q3 and Q4 ahead of the holiday gifting season for fine fragrances.
Health & Biosciences
- Segment name: Health & Biosciences
- Revenue driver formula: Prior Year Revenue x (1 + Volume Growth + Price/Mix Impact)
- Historical growth rate: 6% to 8% currency-neutral growth.
- Key growth levers and headwinds: Structural growth in probiotics, cultures, and animal nutrition, driven by global health and wellness trends.
- Pricing dynamics: High pricing power due to the proprietary, patent-protected nature of biological cultures.
- Revenue recognition notes: Point in time upon transfer of control.
- Seasonality: Generally consistent throughout the year.
Pharma Solutions (Discontinued Operations)
- Segment name: Pharma Solutions
- Revenue driver formula: Stub period revenue (January to May 2025) prior to divestiture close.
- Historical growth rate: ~10% to 12% prior to sale.
- Key growth levers and headwinds: Divested to Roquette; model must handle the removal of this revenue stream post-Q2 2025.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Raw materials (natural extracts, synthetic chemicals, agricultural commodities), direct manufacturing labour, plant overhead, and inbound freight.
- Gross margin range: 32% to 36% (improving recently due to productivity gains and volume leverage).
- Key input costs and commodity exposures: Citrus oils, petrochemical derivatives, soy, and energy costs.
- How COGS scales with revenue: Largely linear, though gross margins expand during periods of high volume growth due to fixed manufacturing overhead absorption.
Operating Expenses
- R&D: Approximately 4.5% to 5.0% of revenue. Crucial for maintaining the product pipeline and winning new customer briefs. Mostly expensed as incurred.
- SG&A: Approximately 15% to 17% of revenue. Driven by global sales force headcount, marketing, and corporate administrative costs.
- Depreciation & Amortisation: Exceptionally high (often 8% to 10% of revenue) due to the massive intangible asset base created by the DuPont N&B and Frutarom acquisitions.
- Restructuring / one-time charges: Frequent and material. The company regularly reports restructuring charges and significant goodwill impairments (e.g., $1.15 billion impairment in 2025).
Margin Profile
- Gross margin: 32% to 36%.
- Adjusted Operating EBITDA margin: 18% to 20% consolidated. Segment margins vary widely: Health & Biosciences (~30%), Scent (~21%), Nourish (~14%).
- Margin trend: Expanding. The company is realising productivity gains and shedding lower-margin businesses to improve the consolidated profile.
Balance Sheet Structure
- Total assets: Approximately $30 billion to $35 billion, heavily skewed toward intangibles.
- Key asset categories: Goodwill and intangible assets make up over 60% of total assets, a legacy of transformational M&A.
- Working capital profile:
- Days Sales Outstanding (DSO): 55 to 65 days.
- Days Inventory Outstanding (DIO): 100 to 120 days. High inventory is required to secure natural raw materials that have single annual harvest cycles.
- Days Payable Outstanding (DPO): 60 to 75 days.
- Net working capital as % of revenue: 20% to 25%.
- Working capital dynamic: Positive working capital. Growth consumes cash due to the heavy inventory requirements of the natural ingredients supply chain.
- PP&E: Represents global manufacturing and R&D facilities. Useful lives range from 10 to 40 years for buildings and 3 to 20 years for machinery.
Capital Expenditure & Investment
- Capex as % of revenue: 4.0% to 5.0%.
- Maintenance capex vs. growth capex: Approximately 50% maintenance, 50% growth (capacity expansion for biosciences and flavours).
- Major capex programmes: Expanding Latin American footprint (e.g., new enzyme hub and application labs in Brazil).
- M&A pattern: Historically a transformational acquirer (DuPont N&B, Frutarom). Currently in a strict divestiture phase (Pharma Solutions, Savory Solutions, Cosmetic Ingredients) to repair the balance sheet.
Debt & Capital Structure
- Total debt: Gross debt was ~$10 billion at the end of 2024, reduced dramatically to ~$4.7 billion by Q3 2025 following the Pharma Solutions divestiture proceeds.
- Debt/EBITDA ratio: Target is Net Debt to Credit-Adjusted EBITDA below 3.0x (achieved in mid-2025).
- Credit rating: Investment grade (BBB- / Baa3), which the company is highly focused on defending.
- Key debt instruments: Senior unsecured notes, term loans, and a revolving credit facility.
- Interest rate profile: Predominantly fixed-rate bonds, with a weighted average cost of debt around 4.5% to 5.5%.
- Share repurchase programme: Suspended. Capital allocation is entirely focused on debt reduction.
- Dividend policy: The dividend was halved in 2024 to $1.60 per share annually to preserve cash for deleveraging.
Cash Flow Characteristics
- Operating cash flow conversion: OCF is typically $1.0 billion to $1.3 billion annually.
- Free cash flow margin: 5% to 8% of revenue.
- Major non-cash items: Massive D&A add-backs, frequent goodwill impairments, and deferred taxes.
- Working capital cash flow impact: Inventory builds often act as a significant use of cash during inflationary periods or supply chain disruptions.
- Cash tax rate: Typically lower than the statutory rate due to global tax planning and the amortisation of tax-deductible goodwill in certain jurisdictions.
Sheet Structure
- Assumptions: Hardcoded drivers for macro variables, segment growth rates, margin targets, working capital days, and WACC.
- Revenue Build: Segment-level forecasting for Nourish, Scent, Health & Biosciences, and a stub-period calculation for Pharma Solutions.
- Income Statement: GAAP and Non-GAAP (Adjusted Operating EBITDA) views, explicitly separating out amortisation of acquisition-related intangibles and restructuring charges.
- Balance Sheet: Standard asset, liability, and equity line items, with a detailed breakout of Goodwill and Intangible Assets.
- Cash Flow Statement: Indirect method starting from Net Income, highlighting the massive D&A add-back and the cash proceeds from the 2025 divestitures.
- Debt Schedule: Tranche-by-tranche debt build, calculating interest expense and modelling the massive 2025 principal paydowns using divestiture proceeds.
- Working Capital: Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO.
- Depreciation & Amortisation: Waterfall schedules for PP&E capex and the run-off of acquisition-related intangible assets.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price.
Key Financial Relationships
- `Nourish Revenue = Prior Year Nourish Revenue * (1 + Nourish Volume Growth + Nourish Price/Mix)`
- `Scent Revenue = Prior Year Scent Revenue * (1 + Scent Volume Growth + Scent Price/Mix)`
- `Health & Biosciences Revenue = Prior Year H&B Revenue * (1 + H&B Volume Growth + H&B Price/Mix)`
- `Pharma Solutions Revenue = IF(Year=2025, 2024 Revenue * (5/12) * (1 + Growth Rate), 0)`
- `Consolidated Adjusted Operating EBITDA = Sum(Segment Adjusted Operating EBITDA) - Unallocated Corporate Expenses`
- `Segment Adjusted Operating EBITDA = Segment Revenue * Segment Adjusted EBITDA Margin`
- `Gross Profit = Total Revenue - (Total Revenue * COGS %)`
- `Amortisation of Intangibles = Prior Year Intangibles Balance * Blended Amortisation Rate`
- `Interest Expense = Average Total Debt * Weighted Average Interest Rate`
- `Accounts Receivable = (Total Revenue / 365) * DSO`
- `Inventory = (COGS / 365) * DIO`
- `Accounts Payable = (COGS / 365) * DPO`
- `Free Cash Flow = Cash Flow from Operations - Capital Expenditures`
- `Net Debt = Total Short-Term Debt + Total Long-Term Debt - Cash and Cash Equivalents`
- `Leverage Ratio = Net Debt / Consolidated Adjusted Operating EBITDA`
Cross-Sheet Dependencies
- The Assumptions sheet dictates the growth and margin profiles on the Revenue Build and Income Statement.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- The Cash Flow Statement calculates the change in cash and debt paydowns, which feed the Balance Sheet and Debt Schedule.
- The Debt Schedule calculates Interest Expense, which flows back to the Income Statement. This creates a circular reference that must be managed with a toggle switch.
- The Working Capital sheet uses Revenue and COGS from the Income Statement to calculate balance sheet accounts, and the period-over-period changes flow to the Cash Flow Statement.
Sign Convention
- Revenue and Assets: Entered and displayed as positive numbers.
- Expenses (COGS, SG&A, Interest): Entered as positive numbers in their specific build schedules, but subtracted in aggregation formulas (e.g., Gross Profit = Revenue - COGS).
- Liabilities and Equity: Entered and displayed as positive numbers.
- Cash Flow Statement: Cash inflows (e.g., Net Income, D&A, Divestiture Proceeds) are positive. Cash outflows (e.g., Capex, Dividends, Debt Repayment, Working Capital increases) are negative.
Things Most Likely to Go Wrong
- Pharma Solutions Divestiture Timing: The $2.85 billion sale to Roquette closed in May 2025. The model must accurately reflect a 5-month stub period for revenue and EBITDA in 2025, and inject the ~$2.6 billion net cash proceeds into the cash flow statement to pay down debt.
- Nourish Segment Restructuring: IFF reorganised Nourish into "Taste" and "Food Ingredients" in 2025. If modelling historicals, the builder must ensure apples-to-apples comparisons or clearly note the pro-forma mapping.
- GAAP vs. Non-GAAP Distortions: IFF's GAAP earnings are heavily distorted by massive intangible amortisation and frequent goodwill impairments (e.g., $1.15 billion in 2025). The model must explicitly build to Adjusted Operating EBITDA to reflect true cash-generating capacity.
- Working Capital Drag: IFF requires high inventory levels (DIO > 100 days). Failing to model the cash drag of inventory builds during growth phases will overstate Free Cash Flow.
- Interest Expense Circularity: The massive debt paydown in 2025 drastically reduces interest expense. The model must accurately average the debt balance in 2025 to avoid overstating interest costs.
- Dividend Policy: The dividend was cut to $1.60 per share in 2024. Projecting historical dividend growth rates will drain cash incorrectly; the model must hardcode the new, lower dividend policy.
- Assets Held for Sale: Divested entities (like Soy Crush) are often moved to "Assets Held for Sale" on the balance sheet prior to closing, which can confuse historical working capital calculations.
Validation Checks
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Net Debt to Adjusted Operating EBITDA should drop below 3.0x by the end of 2025 due to the Pharma Solutions divestiture proceeds."
- "Consolidated Adjusted Operating EBITDA margin should remain between 18.0% and 21.0%."
- "Capex as a percentage of revenue should remain between 4.0% and 5.0%."
- "Days Inventory Outstanding (DIO) should remain above 100 days; flag if it drops below 90 days as this is unrealistic for their supply chain."
- "Total Revenue in 2025 should show a YoY decline due to the removal of Pharma Solutions, despite underlying organic growth in core segments."
- "Dividend payout should equal exactly $1.60 per share multiplied by the outstanding share count."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Nourish Organic Growth | 3.5 | % | Mid-point of recent historical currency-neutral growth and recovery in flavours. |
| Scent Organic Growth | 7.0 | % | Continued strong momentum in fine fragrances and consumer goods. |
| Health & Biosciences Growth | 6.5 | % | Structural tailwinds in probiotics and enzymes. |
| Nourish Adj. EBITDA Margin | 14.5 | % | Slight expansion from 2024 levels due to productivity initiatives. |
| Scent Adj. EBITDA Margin | 21.5 | % | Stable margin profile based on 2024 actuals. |
| H&B Adj. EBITDA Margin | 30.0 | % | High-margin proprietary biological products. |
| SG&A as % of Revenue | 16.0 | % | Historical average, reflecting global sales and administrative footprint. |
| R&D as % of Revenue | 4.5 | % | Required investment to maintain innovation pipeline. |
| Days Sales Outstanding (DSO) | 60 | Days | Based on historical receivables relative to revenue. |
| Days Inventory Outstanding (DIO) | 110 | Days | High inventory requirement for natural raw materials. |
| Days Payable Outstanding (DPO) | 65 | Days | Based on historical payable trends. |
| Capex as % of Revenue | 4.5 | % | Management guidance for maintenance and growth investments. |
| Effective Tax Rate | 20.0 | % | Adjusted effective tax rate excluding one-time impairment impacts. |
| Annual Dividend per Share | 1.60 | $ | Hardcoded based on the 2024 dividend cut announcement. |
| Weighted Average Cost of Debt | 5.0 | % | Blended rate of outstanding senior notes and term loans. |
| WACC | 8.5 | % | Standard discount rate for specialty chemical peers. |
| Terminal Growth Rate | 2.0 | % | Long-term GDP-aligned growth for consumer staple inputs. |
Data Sources & Benchmarks
- Filings: SEC EDGAR (IFF 10-K, 10-Q, and 8-K filings), IFF Investor Relations website.
- Key Peers: Givaudan (GIVN.SW), Symrise (SY1.DE), dsm-firmenich (DSFIR.AS).
- Industry Data: Consumer Packaged Goods (CPG) volume trends, global agricultural commodity pricing (for raw material input costs).
- Consensus Estimates: Bloomberg or FactSet for forward-looking segment revenue and EBITDA margins.
Sources
- IFF 2024 Form 10-K and Q4 2024 Earnings Release (February 2025).
- IFF Q3 2025 Form 10-Q and Earnings Release (November 2025).
- Press Release: IFF Announces Sale of its Pharma Solutions Business to Roquette (March 2024).
- Press Release: IFF Completes Divestiture of Pharma Solutions Business Unit (May 2025).
Do more with the International Flavors & Fragrances model
Frequently asked
What does International Flavors & Fragrances (IFF) do?+
International Flavors & Fragrances (IFF) is a global leader specializing in the creation of value-added ingredients for various markets, including food, beverage, health, biosciences, and scent. The company develops proprietary formulations that serve as essential, low-cost components in consumer packaged goods.
What are the primary revenue drivers for International Flavors & Fragrances?+
IFF's revenue is primarily driven by its Nourish segment, which accounts for approximately 51% of revenue, followed by Scent at 21% and Health & Biosciences at 19%. The company operates a B2B model characterized by high R&D intensity, sticky customer relationships, and significant pricing power across its globally diversified sales.
What is the assumed capital expenditure as a percentage of revenue in the IFF financial model?+
The financial model for International Flavors & Fragrances assumes capital expenditure as a percentage of revenue to be approximately 4.03%. This Capex is roughly split 50% for maintenance and 50% for growth, particularly focusing on capacity expansion in biosciences and flavors.
What is the projected revenue growth rate used in the International Flavors & Fragrances financial model?+
The International Flavors & Fragrances financial model incorporates a projected revenue growth rate of 20%. This assumption is crucial for forecasting the company's future financial performance and its path to deleveraging and margin recovery.
What is the main purpose of the International Flavors & Fragrances financial model?+
The primary purpose of this financial model is to provide a comprehensive platform for equity valuation and credit analysis of International Flavors & Fragrances. It enables analysts to forecast the company's deleveraging trajectory and margin recovery following significant business changes like divestitures and restructuring.
Is an Excel model available for International Flavors & Fragrances, and what is its forecast horizon?+
Yes, a downloadable Excel model is available for International Flavors & Fragrances. This model provides a forecast horizon spanning from fiscal year 2026 through fiscal year 2030, offering detailed projections for future analysis.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Chemicals Company Financial Models
Browse another company in the same sector.
Albemarle
Albemarle Corporation is a global specialty chemicals company and one of the world's largest producers of lithium and bromine.
Air Products
Air Products and Chemicals, Inc.
CF Industries
CF Industries Holdings, Inc.
Corteva
Corteva is a global pure-play agriculture company that provides farmers with a comprehensive portfolio of seed, crop protection, and digital solutions built on advanced genetics, biologicals, and synthetic chemistry.
DuPont
DuPont is a global advanced materials and engineered solutions company that provides highly specified products to regulated and performance-critical industries, including medical packaging, water filtration, and engineered materials for aerospace and construction.
Dow
Dow is a global materials science company that produces plastics, chemicals, and agricultural products for packaging, infrastructure, mobility, and consumer applications, operating integrated manufacturing sites that convert hydrocarbon feedstocks into value-added chemical products.
Ecolab
Ecolab is a global leader in water, hygiene, and infection prevention solutions and services, providing proprietary chemicals and dispensing equipment to industrial, hospitality, healthcare, and life sciences customers via a direct field sales and service force.
Linde
Linde plc is the world's largest industrial gas and engineering company, producing atmospheric and process gases for a variety of end markets including chemicals, manufacturing, healthcare, and electronics.
Explore more Manufacturing financial model templates.
